President Trump's executive order and CMS initiatives mark significant moves to reduce drug prices through broadened Medicare price negotiations including Part B drugs, impacting pharmaceutical industry dynamics and regulatory compliance.
President Trump signs an executive order setting a 30-day deadline for drugmakers to lower prescription drug prices in the U.S. or face new federal limits tied to international prices.
The Trump administration plans to reintroduce a 'most favored nation' drug pricing model for Medicare, aiming to align U.S. drug prices with lower international rates. This strategy faces industry opposition but could complement existing Medicare drug price negotiations to reduce costs.
The Medicare for All Act aims to expand Medicare to cover all Americans comprehensively, eliminating premiums and deductibles while addressing health care affordability and systemic inefficiencies.
